Ticker Search:  Getting Started | Register | Videos | Newsletter | Partners | Login    

Basics
Kyverna Therapeutics, Inc. Common Stock
IPO Date: February 9, 2024
Sector: Healthcare
Industry: Biotech
Market Cap: $111.5M
Activated in VL: True
Average Daily Range
Avg Daily Range: $0.36 | 4.20%
Avg Daily Range (30 D): $0.10 | 4.55%
Avg Daily Range (90 D): $0.10 | 4.05%
Institutional Daily Volume
Avg Daily Volume: .35M
Avg Daily Volume (30 D): .29M
Avg Daily Volume (90 D): .3M
Trade Size
Avg Trade Size (Sh.): 96
Avg Trade Size (Sh.) (30 D): 133
Avg Trade Size (Sh.) (90 D): 126
Institutional Trades
Total Inst.Trades: 108
Avg Inst. Trade: $1.86M
Avg Inst. Trade (30 D): $3.27M
Avg Inst. Trade (90 D): $3.27M
Avg Inst. Trade Volume: .14M
Avg Inst. Trades (Per Day): 1
Market Closing Trades
Avg Closing Trade: $2.67M
Avg Closing Trade (30 D): $3.06M
Avg Closing Trade (90 D): $3.06M
Avg Closing Volume: 213.96K
       
News
Mar 18, 2025 @ 8:48 PM
Notice to Long-Term Shareholders of Archer-Daniels...
Source: Grabar Law Office
Mar 13, 2025 @ 10:21 PM
Long-Term Shareholder Notice: Fluence Energy, Inc....
Source: Grabar Law Office
Mar 5, 2025 @ 6:00 PM
CAR T-cell Therapy Clinical Trial Pipeline Experie...
Source: Delveinsight
Feb 6, 2025 @ 6:51 PM
Investors in Kyverna Therapeutics, Inc. Should Con...
Source: The Gross Law Firm
Feb 3, 2025 @ 9:00 PM
KYTX INVESTOR ALERT: Bronstein, Gewirtz & Grossman...
Source: Bronstein, Gewirtz & Grossman, Llc
Financials
  TTM Q1 2025 Q4 2024
Basic EPS $-3.38 $-1.03 $-.88
Diluted EPS $-3.38 $-1.03 $-.88
Revenue $ M $ M $ M
Gross Profit $ $ $
Net Income / Loss $ -145.42M $ -44.64M $ -37.49M
Operating Income / Loss $ -160.65M $ -47.41M $ -41.04M
Cost of Revenue $ $ $
Net Cash Flow $ -167.44M $ -39.75M $ -8.05M
PE Ratio